Läkemedelsrelaterad osteonekros i käkarna, del 2: Skandinavisk kohort ska öka kunskapen
Sammanfattning
Osteonecrosis of the jaws (ONJ) is a serious complication related to anti-resorptive therapy. In
Scandinavia, there is a significant need to ascertain the occurrence of ONJ as reports concerning
side-effects are lacking and to also improve our knowledge
when treating the patients. This paper describes the establishment of a Scandinavian cohort of new
patients with ONJ related to anti-resorptive treatment in Denmark, Norway and Sweden between 2011
and 2019. The starting point for the study was to support an ongoing drug safety study of denosumab
(XGEVA®) and zoledronate (Zometa®) in the clinical treatment of cancer with bone metastases. Using
this established infrastructure, a Scandinavian ONJ cohort, including patients with ONJ related to any
type of anti-resorptive treatment was developed. There are a total of 199 departments or clinics for oral
and maxillofacial surgery and hospital dentistry in Denmark, Norway and Sweden, and treatment
regimens and referrals for ONJ patients differs somewhat between the three countries. In each country
efforts have been made to provide information to the
respective dental associations, including production of a web page. Data collection is ongoing and
it is expected that this comprehensive, systematic collection of data on ONJ patients can form the
basis of research leading to a greater understanding of the condition and to better treatment
appraoches.